menactra
sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - solution for injection - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y, and w-135 menactra vaccine does not prevent n meningitidis serogroup b disease.
menactra
pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.
menveo vaccine powder and solution for solution for injection
glaxo saudi arabia ltd., saudi arabia - meningococcal group a (neisseria meningitidis) polysaccharide vaccine,meningococcal group c (neisseria meningitidis) polysaccharide,meningococcal group w (neisseria meningitidis) polysaccharide,meningococcal group y (neisseria meningitidis) polysaccharide - powder and solution for solution for injection - 10,5,5,5 µg,
menactra solution
sanofi pasteur limited - meningococcal polysaccharide-diphtheria toxoid conjugate, group a; meningococcal polysaccharide-diphtheria toxoid conjugate, group c; meningococcal polysaccharide-diphtheria toxoid conjugate, group y; meningococcal polysaccharide-diphtheria toxoid conjugate, group w 135 - solution - 4.0mcg; 4.0mcg; 4.0mcg; 4.0mcg - meningococcal polysaccharide-diphtheria toxoid conjugate, group a 4.0mcg; meningococcal polysaccharide-diphtheria toxoid conjugate, group c 4.0mcg; meningococcal polysaccharide-diphtheria toxoid conjugate, group y 4.0mcg; meningococcal polysaccharide-diphtheria toxoid conjugate, group w 135 4.0mcg - vaccines
menomune-a/c/y/w-135 powder for solution
sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - powder for solution - 500mcg; 500mcg; 500mcg; 500mcg - meningococcal polysaccharide antigen group a 500mcg; meningococcal polysaccharide antigen group c 500mcg; meningococcal polysaccharide antigen group y 500mcg; meningococcal polysaccharide antigen group w-135 500mcg - vaccines
menomune-a/c/y/w-135 kit
sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - kit - 50mcg; 50mcg; 50mcg; 50mcg - meningococcal polysaccharide antigen group a 50mcg; meningococcal polysaccharide antigen group c 50mcg; meningococcal polysaccharide antigen group y 50mcg; meningococcal polysaccharide antigen group w-135 50mcg - vaccines
menomune acyw-135 vaccine
sanofi-aventis new zealand limited - neisseria meningitidis group a polysaccharide 50ug; neisseria meningitidis group c polysaccharide 50ug; neisseria meningitidis group w135 polysaccharide 50ug; neisseria meningitidis group y polysaccharide 50ug - injection with diluent - 0.5 ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: lactose monohydrate sodium chloride purified water - menomune® acyw-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by neisseria meningitidis groups a, c, y and w-135, the major manifestation being meningococcal meningitis. vaccination may be considered for the following individuals: · travellers to countries recognised as having highly endemic or epidemic disease. · control of epidemics of infection caused by neisseria meningitidis groups a, c, y and w-135 in confined communities. · individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · close contacts of persons with meningococcal disease due to groups a, c, y and w-135, as an adjunct to appropriate chemoprophylaxis.
menveo
glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solution for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen
nimenrix kit
pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines